LAG3 and neoplasm: Therefore, it is not surprising that the dominant effect of LAG-3 blockade and the relatively low effect of PD-1 blockade that we see deviates from the results in animal studies (36) and the outstanding clinical effects observed with PD-1 blockade as monotherapy or in combination with antineoplastic agents in clinical trials for various tumor entities.